Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
Authors: Cheng Ying , Zhang Wei , Wu Lin , Zhou Caicun , Wang Donglin , Xia Bing , Bi Minghong , Fu Xiuhua , Li Chong , Lv Dongqing , Zhao Yanqiu , Chen Gongyan , Yi Tienan , Huang Jianan , Li Min , Yang Runxiang , Huang Xiaoping , Wang Ye , Zhang Mingjun , Pan Yueyin , Sun Yilan , Hu Sheng , Zhang Xiqin , Zhou Min , Fang Jian , Jin Faguang , Liu Yunpeng , Li Yinyin , Zhang Zhihong , Hu Jie , Liu Laiyu , Wang Rui , Li Yan , Gu Kangsheng , Ding Cuimin , Fan Qingxia , Zhang Guojun , Chen Yongxing , Jiang Liyan , Zheng Wei-E. , Chen Shaoshui , Huang Cheng , Han Zhigang , Yang Hong , Wang Jianfang , Wang Baocheng , Wu Huita , Bao Yongxing , Li Manxiang , Luo Xianming , Gu Shanshan , Yu Wenbo , Xu Kai , Zhang Simo , Yu Jianjun 
Published: November 2024

Importance

Patients with extensive-stage small cell lung cancer (ES-SCLC) have poor prognoses and unmet medical needs.

Objective

To evaluate the efficacy and safety of toripalimab plus etoposide and platinum-based chemotherapy (EP) vs placebo plus EP as a first-line treatment for patients with ES-SCLC.

Design, Setting, and Participants

This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (EXTENTORCH study) enrolled patients from September 26, 2019, to May 20, 2021, and was conducted at 49 sites in China. Eligible patients had histologically or cytologically confirmed ES-SCLC without previous systemic antitumor therapy for ES-SCLC. Data were analyzed between May 6, 2023, and June 1, 2024.

Interventions

Patients were randomized (1:1) to receive toripalimab, 240 mg, or placebo plus EP every 3 weeks for up to 4 to 6 cycles, followed by maintenance with toripalimab or placebo until disease progression, intolerable toxic effects, or up to 2 years of treatment.

Main Outcomes and Measures

The primary end points were investigator-assessed progression-free survival (PFS) and overall survival (OS). Whole-exome sequencing results identified correlative biomarkers for clinical efficacy.

Results

Among 595 screened patients, 442 eligible patients were randomized (median [range] age, 63 [30-77] years; 366 [82.8%] male); 223 patients were randomized to toripalimab plus EP, and 219 to placebo plus EP. By April 20, 2023, the median (range) survival follow-up was 13.7 (0.0-42.7) months. Compared with placebo, toripalimab improved investigator-assessed PFS (hazard ratio [HR], 0.67 [95% CI, 0.54-0.82]; P &amp;lt; .001), and significantly reduced the risk of death (HR, 0.80 [95% CI, 0.65-0.98]; P = .03). The median OS was 14.6 (95% CI, 12.9-16.6) months in the toripalimab group vs 13.3 (95% CI, 11.8-14.4) months in the placebo group. Whole-exome sequencing results from 300 patients identified low intratumor heterogeneity, HLA-A11+ HLA-B62− haplotype, wild-type KMT2D and COL4A4, or sequence variations in CTNNA2 or SCN4A correlated with favorable PFS and OS in the toripalimab group. No new safety signals were observed. Grade 3 or higher treatment-emergent adverse event incidence was similar between the toripalimab and placebo safety set groups (199 of 222 patients [89.6%] vs 193 of 216 patients [89.4%], respectively).

Conclusions and Relevance

In this phase 3 randomized clinical trial, adding toripalimab to first-line chemotherapy demonstrated significant improvements in PFS and OS for patients with ES-SCLC. The treatment exhibited an acceptable safety profile, supporting this combination regimen as a new treatment option for patients with ES-SCLC.

Trial Registration

ClinicalTrials.gov Identifier: NCT04012606